Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) ...

Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

In the Lehigh Valley, cases of the flu and RSV are particularly prevalent compared with many other parts of the state.

Vaccines and monoclonal antibodies are reducing RSV hospitalizations, but high costs and limited access in low-income ...

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

Cases of the flu, rsv and covid are spreading across the country and this comes at a time, when vaccination rates are low. As ...

Flu season is here in New Jersey, but other illnesses are in full swing in the Garden State. Here are the symptoms and how ...

When broken down by state, most of the country is experiencing elevated respiratory illness, including a few states with ...

The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.